Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus low-dose CAG for myelodysplastic syndrome
ChiCTR-TNC-11001566Phase 2Completed
- Sponsor
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University
- Start
- Sep 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine, cytarabine, aclarubicin and granulocyte colony-stimulating factor in myelodysplastic syndrome (MDS) (2 arms), sponsored by Department of Hematology, The First Affiliated Hospital of Nanjing Medical University. Started Sep 2011; status: completed.
02
Drugs
decitabinecytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-TNC-11001566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-11001566.